Neuraxis, Inc. completed a stock option exchange approved in June 2026, converting 1,319,394 options into restricted stock units (RSUs) on a one-for-one basis. On July 24, 2026, the exchange became effective, resulting in immediate vesting of RSUs for CEO Brian Carrico (199,188), CMO Adrian Miranda (199,106), and CRO Thomas Carrico (193,678). Subsequently, on August 13, 2026, the Compensation Committee granted additional equity awards: RSUs to executive officers including Brian Carrico (193,329), CFO Timothy Henrichs (141,479), Adrian Miranda (133,341), and Thomas Carrico (135,906), vesting over three years. The company also granted 127,120 shares of common stock to independent directors to address historical compensation below market levels. Neuraxis operates in the healthcare sector, developing medical devices for neurological conditions.

Neuraxis, Inc. declared a stock dividend for the second quarter of 2026 on its Series B Preferred Stock, which will be stock in the form of common stock. Approximately 80,463 shares of common stock are expected to be issued, with fractional shares being settled in cash. The dividend is payable on July 29, 2026, to holders of record as of July 21, 2026, based on a conversion factor of conversion factor of $2.38 per share. Neuraxis, Inc. operates in the biotechnology/medical technology sector.